
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7303721/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection. JAMA - Journal of the American Medical Association, 2007, 298, 743.	3.8	581
2	Population-Based Study of Human Papillomavirus Infection and Cervical Neoplasia in Rural Costa Rica. Journal of the National Cancer Institute, 2000, 92, 464-474.	3.0	515
3	The carcinogenicity of human papillomavirus types reflects viral evolution. Virology, 2005, 337, 76-84.	1.1	487
4	HPV DNA Testing in Cervical Cancer Screening. JAMA - Journal of the American Medical Association, 2000, 283, 87.	3.8	466
5	Rapid Clearance of Human Papillomavirus and Implications for Clinical Focus on Persistent Infections. Journal of the National Cancer Institute, 2008, 100, 513-517.	3.0	436
6	Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica. PLoS ONE, 2013, 8, e68329.	1.1	387
7	MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5874-5878.	3.3	385
8	Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer, 2004, 100, 1035-1044.	2.0	367
9	A Prospective Study of Age Trends in Cervical Human Papillomavirus Acquisition and Persistence in Guanacaste, Costa Rica. Journal of Infectious Diseases, 2005, 191, 1808-1816.	1.9	354
10	Epidemiologic Profile of Typeâ€5pecific Human Papillomavirus Infection and Cervical Neoplasia in Guanacaste, Costa Rica. Journal of Infectious Diseases, 2005, 191, 1796-1807.	1.9	322
11	Longitudinal Study of Human Papillomavirus Persistence and Cervical Intraepithelial Neoplasia Grade 2/3: Critical Role of Duration of Infection. Journal of the National Cancer Institute, 2010, 102, 315-324.	3.0	320
12	Evaluation of Human Papillomavirus Antibodies and Risk of Subsequent Head and Neck Cancer. Journal of Clinical Oncology, 2013, 31, 2708-2715.	0.8	280
13	Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine. Journal of the National Cancer Institute, 2011, 103, 1444-1451.	3.0	274
14	Host and viral genetics and risk of cervical cancer: a review. Virus Research, 2002, 89, 229-240.	1.1	270
15	An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine, 2008, 26, K53-K61.	1.7	266
16	Cigarette Smoking and Variations in Systemic Immune and Inflammation Markers. Journal of the National Cancer Institute, 2014, 106, .	3.0	255
17	Efficacy of fewer than three doses of an HPV-16/18 ASO4-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncology, The, 2015, 16, 775-786.	5.1	247
18	Human Papillomavirus Infection with Multiple Types: Pattern of Coinfection and Risk of Cervical Disease. Journal of Infectious Diseases, 2011, 203, 910-920.	1.9	245

#	Article	IF	CITATIONS
19	A Prospective Study of Human Papillomavirus (HPV) Type 16 DNA Detection by Polymerase Chain Reaction and Its Association with Acquisition and Persistence of Other HPV Types. Journal of Infectious Diseases, 2001, 183, 8-15.	1.9	242
20	Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet, The, 2013, 382, 877-887.	6.3	239
21	A Population-Based Prospective Study of Carcinogenic Human Papillomavirus Variant Lineages, Viral Persistence, and Cervical Neoplasia. Cancer Research, 2010, 70, 3159-3169.	0.4	221
22	HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis. Cell, 2017, 170, 1164-1174.e6.	13.5	221
23	Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. Journal of Experimental Medicine, 2005, 201, 1069-1075.	4.2	209
24	Genome-Wide Expression Profiling Reveals EBV-Associated Inhibition of MHC Class I Expression in Nasopharyngeal Carcinoma. Cancer Research, 2006, 66, 7999-8006.	0.4	207
25	Specific Antibody Levels at the Cervix During the Menstrual Cycle of Women Vaccinated With Human Papillomavirus 16 Virus-Like Particles. Journal of the National Cancer Institute, 2003, 95, 1128-1137.	3.0	205
26	Utility of liquid-based cytology for cervical carcinoma screening. Cancer, 1999, 87, 48-55.	2.0	199
27	Evaluation of Risk Factors for Nasopharyngeal Carcinoma in High-Risk Nasopharyngeal Carcinoma Families in Taiwan. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 900-905.	1.1	198
28	Circulating Inflammation Markers and Prospective Risk for Lung Cancer. Journal of the National Cancer Institute, 2013, 105, 1871-1880.	3.0	198
29	Association of HLA Class I and II Alleles and Extended Haplotypes With Nasopharyngeal Carcinoma in Taiwan. Journal of the National Cancer Institute, 2002, 94, 1780-1789.	3.0	193
30	The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: A need for reappraisal. Virus Research, 2009, 143, 209-221.	1.1	187
31	Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial. Cancer Prevention Research, 2013, 6, 1242-1250.	0.7	185
32	Etiology of Nasopharyngeal Carcinoma: A Review. Epidemiologic Reviews, 1993, 15, 466-485.	1.3	183
33	Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine, 2006, 24, S171-S177.	1.7	183
34	Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 1997, 1, 362-375.	0.6	183
35	CYP2E1 Genetic Polymorphisms and Risk of Nasopharyngeal Carcinoma in Taiwan. Journal of the National Cancer Institute, 1997, 89, 1207-1212.	3.0	178
36	Seroreactivity to Human Papillomavirus (HPV) Types 16, 18, or 31 and Risk of Subsequent HPV Infection. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 324-327.	1.1	177

#	Article	IF	CITATIONS
37	Genetic predisposition factors and nasopharyngeal carcinoma risk: A review of epidemiological association studies, 2000–2011. Seminars in Cancer Biology, 2012, 22, 107-116.	4.3	173
38	Epstein-Barr Virus (EBV) in Endemic Burkitt's Lymphoma: Molecular Analysis of Primary Tumor Tissue. Blood, 1998, 91, 1373-1381.	0.6	169
39	The Epidemiology of Oral HPV Infection among a Multinational Sample of Healthy Men. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 172-182.	1.1	169
40	Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncology, The, 2011, 12, 862-870.	5.1	168
41	Cellular Immune Responses to Human Papillomavirus (HPV)–16 L1 in Healthy Volunteers Immunized with Recombinant HPVâ€16 L1 Virusâ€Like Particles. Journal of Infectious Diseases, 2003, 188, 327-338.	1.9	159
42	Comparisons of HPV DNA detection by MY09/11 PCR methods. Journal of Medical Virology, 2002, 68, 417-423.	2.5	158
43	Epidemiological Study of Anti-HPV16/18 Seropositivity and Subsequent Risk of HPV16 and -18 Infections. Journal of the National Cancer Institute, 2010, 102, 1653-1662.	3.0	155
44	Chapter 5: Viral and Host Factors in Human Papillomavirus Persistence and Progression. Journal of the National Cancer Institute Monographs, 2003, 2003, 35-40.	0.9	150
45	Risk for High-Grade Cervical Intraepithelial Neoplasia Associated with Variants of Human Papillomavirus Types 16 and 18. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 4-10.	1.1	146
46	Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine, 2008, 26, 4795-4808.	1.7	145
47	Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica. Cancer Discovery, 2011, 1, 408-419.	7.7	143
48	Herpes simplex virus type 2: A possible interaction with human papillomavirus types 16/18 in the development of invasive cervical cancer. International Journal of Cancer, 1991, 49, 335-340.	2.3	135
49	High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. International Journal of Cancer, 2007, 121, 2787-2793.	2.3	134
50	Human Papillomavirus Type 16 and 18 Variants: Race-Related Distribution and Persistence. Journal of the National Cancer Institute, 2006, 98, 1045-1052.	3.0	133
51	HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine, 2011, 29, 2011-2014.	1.7	130
52	Distribution of human papillomavirus types 16 and 18 variants in squamous cell carcinomas and adenocarcinomas of the cervix. Cancer Research, 2003, 63, 7215-20.	0.4	127
53	Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia. International Journal of Cancer, 2013, 132, 1412-1422.	2.3	123
54	Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer, 2008, 113, 1980-1993.	2.0	121

#	Article	IF	CITATIONS
55	Elevated antibody titers to Epstein-Barr virus prior to the diagnosis of Epstein-Barr-virus-associated gastric adenocarcinoma. International Journal of Cancer, 1995, 60, 642-644.	2.3	117
56	Cigarette smoking, alcohol consumption and risk of nasopharyngeal carcinoma in Taiwan. Cancer Causes and Control, 1999, 10, 201-207.	0.8	116
57	Dietary exposure to nitrite and nitrosamines and risk of nasopharyngeal carcinoma in Taiwan. , 2000, 86, 603-609.		116
58	Clinical Trial Designs for the Early Clinical Development of Therapeutic Cancer Vaccines. Journal of Clinical Oncology, 2001, 19, 1848-1854.	0.8	113
59	Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix. Cancer, 2003, 98, 814-821.	2.0	112
60	Epidemiologic profile, sexual history, pathologic features, and human papillomavirus status of 103 patients with penile carcinoma. World Journal of Urology, 2013, 31, 861-867.	1.2	110
61	Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. American Journal of Obstetrics and Gynecology, 2016, 215, 212.e1-212.e15.	0.7	108
62	Common Variants in Immune and DNA Repair Genes and Risk for Human Papillomavirus Persistence and Progression to Cervical Cancer. Journal of Infectious Diseases, 2009, 199, 20-30.	1.9	107
63	p53 polymorphism and risk of cervical cancer. Nature, 1998, 396, 531-532.	13.7	105
64	Relationships of Human Papillomavirus Type, Qualitative Viral Load, and Age with Cytologic Abnormality. Cancer Research, 2006, 66, 10112-10119.	0.4	105
65	Defining the genetic susceptibility to cervical neoplasia—A genome-wide association study. PLoS Genetics, 2017, 13, e1006866.	1.5	105
66	Common Genetic Variants and Risk for HPV Persistence and Progression to Cervical Cancer. PLoS ONE, 2010, 5, e8667.	1.1	104
67	Evidence for single-dose protection by the bivalent HPV vaccine—Review of the Costa Rica HPV vaccine trial and future research studies. Vaccine, 2018, 36, 4774-4782.	1.7	103
68	Non-viral risk factors for nasopharyngeal carcinoma in the philippines: Results from a case-control study. International Journal of Cancer, 1993, 55, 722-727.	2.3	99
69	Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing. Cancer, 1997, 81, 89-97.	2.0	99
70	Methylation of Human Papillomavirus Type 16 Genome and Risk of Cervical Precancer in a Costa Rican Population. Journal of the National Cancer Institute, 2012, 104, 556-565.	3.0	99
71	Persistent Human Papillomavirus Infection Is Associated with a Generalized Decrease in Immune Responsiveness in Older Women. Cancer Research, 2006, 66, 11070-11076.	0.4	98
72	Comparison of mRNA and Protein Measures of Cytokines following Vaccination with Human Papillomavirus-16 L1 Virus-like Particles. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 978-981.	1.1	98

#	Article	IF	CITATIONS
73	A large, population-based study of age-related associations between vaginal pH and human papillomavirus infection. BMC Infectious Diseases, 2012, 12, 33.	1.3	96
74	Age-Related Changes of the Cervix Influence Human Papillomavirus Type Distribution. Cancer Research, 2006, 66, 1218-1224.	0.4	95
75	Human Leukocyte Antigen Class I and II Alleles and Risk of Cervical Neoplasia: Results from a Populationâ€Based Study in Costa Rica. Journal of Infectious Diseases, 2001, 184, 1310-1314.	1.9	94
76	Efficacy of the HPV-16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine, 2014, 32, 5087-5097.	1.7	92
77	Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection. Journal of the National Cancer Institute, 2016, 108, djv302.	3.0	92
78	Evaluation of Multiplexed Cytokine and Inflammation Marker Measurements: a Methodologic Study. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1902-1911.	1.1	89
79	Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial. Journal of the National Cancer Institute, 2020, 112, 1038-1046.	3.0	89
80	An Updated Natural History Model of Cervical Cancer: Derivation of Model Parameters. American Journal of Epidemiology, 2014, 180, 545-555.	1.6	87
81	Serologic Response to Helicobacter pylori Proteins Associated With Risk of Colorectal Cancer Among Diverse Populations in the United States. Gastroenterology, 2019, 156, 175-186.e2.	0.6	84
82	Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. Gynecologic Oncology, 2014, 135, 297-304.	0.6	83
83	Behavioral/Lifestyle and Immunologic Factors Associated with HPV Infection among Women Older Than 45 Years. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 3044-3054.	1.1	80
84	Assessment of Human Papillomavirus in Lung Tumor Tissue. Journal of the National Cancer Institute, 2011, 103, 501-507.	3.0	80
85	Body Mass Index, Physical Activity, and Serum Markers of Inflammation, Immunity, and Insulin Resistance. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2840-2849.	1.1	79
86	Epstein-Barr Virus Antibodies and the Risk of Associated Malignancies: Review of the Literature. American Journal of Epidemiology, 2014, 180, 687-695.	1.6	79
87	Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ: British Medical Journal, 2010, 340, c712-c712.	2.4	78
88	Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine, 2008, 26, 3608-3616.	1.7	77
89	Circulating Inflammation Markers, Risk of Lung Cancer, and Utility for Risk Stratification. Journal of the National Cancer Institute, 2015, 107, .	3.0	77
90	Kinetics of the Human Papillomavirus Type 16 E6 Antibody Response Prior to Oropharyngeal Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	77

#	Article	IF	CITATIONS
91	Comparison of Two PCR-Based Human Papillomavirus Genotyping Methods. Journal of Clinical Microbiology, 2008, 46, 3437-3445.	1.8	75
92	Genes Involved in DNA Repair and Nitrosamine Metabolism and Those Located on Chromosome 14q32 Are Dysregulated in Nasopharyngeal Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 2216-2225.	1.1	74
93	Comparison of the SPF 10 -LiPA System to the Hybrid Capture 2 Assay for Detection of Carcinogenic Human Papillomavirus Genotypes among 5,683 Young Women in Guanacaste, Costa Rica. Journal of Clinical Microbiology, 2007, 45, 1447-1454.	1.8	74
94	Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10 000 women in Guanacaste, Costa Rica. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2004, 15, 75-89.	0.6	74
95	Variation of the Killer Cell Immunoglobulin-Like Receptors and HLA-C Genes in Nasopharyngeal Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2673-2677.	1.1	73
96	A Comparison of Cervical and Vaginal Human Papillomavirus. Sexually Transmitted Diseases, 2007, 34, 849-855.	0.8	73
97	Comparison of human papillomavirus genotypes, sexual, and reproductive risk factors of cervical adenocarcinoma and squamous cell carcinoma: Northeastern United States. American Journal of Obstetrics and Gynecology, 2003, 188, 657-663.	0.7	72
98	A Populationâ€Based Study of Vaginal Human Papillomavirus Infection in Hysterectomized Women. Journal of Infectious Diseases, 2004, 190, 458-467.	1.9	72
99	Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial. Journal of the National Cancer Institute, 2018, 110, 205-212.	3.0	71
100	Association of oral contraceptive use and human papillomaviruses in invasive cervical cancers. International Journal of Cancer, 1990, 45, 860-864.	2.3	70
101	Active and Passive Smoking and Risk of Nasopharyngeal Carcinoma: A Population-Based Case-Control Study in Southern China. American Journal of Epidemiology, 2017, 185, 1272-1280.	1.6	68
102	Associations between smoking and adenocarcinomas and squamous cell carcinomas of the uterine cervix (United States). Cancer Causes and Control, 2001, 12, 153-161.	0.8	67
103	Human papillomavirus 16 <scp>E</scp> 6 antibodies are sensitive for human papillomavirus–driven oropharyngeal cancer and are associated with recurrence. Cancer, 2017, 123, 4382-4390.	2.0	67
104	Nasopharyngeal carcinoma and genetic polymorphisms of DNA repair enzymes XRCC1 and hOGG1. Cancer Epidemiology Biomarkers and Prevention, 2003, 12, 1100-4.	1.1	67
105	Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging. Lancet Oncology, The, 2015, 16, e226-e233.	5.1	66
106	Elevated Systemic Levels of Inflammatory Cytokines in Older Women with Persistent Cervical Human Papillomavirus Infection. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1954-1959.	1.1	64
107	A prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphoma. Blood, 2013, 122, 951-957.	0.6	64
108	Chlamydia trachomatis and Risk of Prevalent and Incident Cervical Premalignancy in a Population-Based Cohort. Journal of the National Cancer Institute, 2010, 102, 1794-1804.	3.0	63

#	Article	IF	CITATIONS
109	HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. Vaccine, 2005, 23, 3555-3564.	1.7	60
110	Comprehensive Analysis of Human Leukocyte Antigen Class I Alleles and Cervical Neoplasia in 3 Epidemiologic Studies. Journal of Infectious Diseases, 2002, 186, 598-605.	1.9	59
111	Second Cancers After Squamous Cell Carcinoma and Adenocarcinoma of the Cervix. Journal of Clinical Oncology, 2009, 27, 967-973.	0.8	59
112	Associations of Coffee Drinking with Systemic Immune and Inflammatory Markers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1052-1060.	1.1	59
113	Prognostic Utility of Anti-EBV Antibody Testing for Defining NPC Risk among Individuals from High-Risk NPC Families. Clinical Cancer Research, 2011, 17, 1906-1914.	3.2	58
114	Epstein–Barr Virus Serology as a Potential Screening Marker for Nasopharyngeal Carcinoma among High-Risk Individuals from Multiplex Families in Taiwan. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1213-1219.	1.1	58
115	A cross-sectional study of changes in markers of immunological effects and lung health due to exposure to multi-walled carbon nanotubes. Nanotoxicology, 2017, 11, 395-404.	1.6	58
116	Cervicography screening for cervical cancer among 8460 women in a high-risk population. American Journal of Obstetrics and Gynecology, 1999, 180, 290-298.	0.7	56
117	Epstein-Barr virus seroreactivity among unaffected individuals within high-risk nasopharyngeal carcinoma families in Taiwan. International Journal of Cancer, 2004, 111, 117-123.	2.3	56
118	A Competitive Serological Assay Shows Naturally Acquired Immunity to Human Papillomavirus Infections in the Guanacaste Natural History Study. Journal of Infectious Diseases, 2011, 204, 94-102.	1.9	55
119	Human papillomavirus type 16 E7 protein sensitizes cervical keratinocytes to apoptosis and release of interleukin-11±. Oncogene, 1998, 17, 1195-1205.	2.6	54
120	Human Papillomavirus 16 E6 Antibodies in Individuals without Diagnosed Cancer: A Pooled Analysis. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 683-689.	1.1	54
121	Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial. Lancet Oncology, The, 2020, 21, 1643-1652.	5.1	54
122	Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Virology, 2006, 353, 451-462.	1.1	53
123	Human Papillomavirus Antibodies and Future Risk of Anogenital Cancer: A Nested Case-Control Study in the European Prospective Investigation Into Cancer and Nutrition Study. Journal of Clinical Oncology, 2015, 33, 877-884.	0.8	53
124	Epidemiologic determinants of vaginal pH. American Journal of Obstetrics and Gynecology, 1999, 180, 1060-1066.	0.7	52
125	Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan. Clinical Cancer Research, 2018, 24, 1305-1314.	3.2	52
126	The Natural History of Human Papillomavirus Infection and Cervical Intraepithelial Neoplasia Among Young Women in the Guanacaste Cohort Shortly After Initiation of Sexual Life. Sexually Transmitted Diseases, 2007, 34, 494-502.	0.8	51

#	Article	IF	CITATIONS
127	Human Papillomavirus Types by Age in Cervical Cancer Precursors: Predominance of Human Papillomavirus 16 in Young Women. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 863-865.	1.1	51
128	Prevalence of and Risk Factors for Anal Human Papillomavirus Infection Among Young Healthy Women in Costa Rica. Journal of Infectious Diseases, 2012, 206, 1103-1110.	1.9	51
129	Clustering of Multiple Human Papillomavirus Infections in Women From a Population-Based Study in Guanacaste, Costa Rica. Journal of Infectious Diseases, 2011, 204, 385-390.	1.9	50
130	Association of Aflatoxin and Gallbladder Cancer. Gastroenterology, 2017, 153, 488-494.e1.	0.6	49
131	Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix®. Vaccine, 2012, 31, 165-170.	1.7	48
132	Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. International Journal of Cancer, 2017, 140, 600-610.	2.3	48
133	Screening for human papillomavirusâ€driven oropharyngeal cancer: Considerations for feasibility and strategies for research. Cancer, 2018, 124, 1859-1866.	2.0	48
134	Cytokine and immunoglobulin concentrations in cervical secretions: reproducibility of the Weck-cel collection instrument and correlates of immune measures. Journal of Immunological Methods, 1999, 225, 131-143.	0.6	47
135	Long-Term Persistence of Prevalently Detected Human Papillomavirus Infections in the Absence of Detectable Cervical Precancer and Cancer. Journal of Infectious Diseases, 2011, 203, 814-822.	1.9	47
136	Prevalence of and Risk Factors for Oral Human Papillomavirus Among Young Women in Costa Rica. Journal of Infectious Diseases, 2013, 208, 1643-1652.	1.9	47
137	A GWAS Meta-analysis and Replication Study Identifies a Novel Locus within <i>CLPTM1L/TERT</i> Associated with Nasopharyngeal Carcinoma in Individuals of Chinese Ancestry. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 188-192.	1.1	45
138	Fixation and cryopreservation of whole blood and isolated mononuclear cells: Influence of different procedures on lymphocyte subset analysis by flow cytometry. Cytometry Part B - Clinical Cytometry, 2005, 63B, 47-55.	0.7	43
139	Pathological characteristics of cervical adenocarcinoma in a multi-center U.Sbased study. Gynecologic Oncology, 2006, 103, 541-546.	0.6	43
140	Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials. Journal of the National Cancer Institute, 2017, 109, djw300.	3.0	43
141	Cervical concentrations of interleukin-10 and interleukin-12 do not correlate with plasma levels. Journal of Clinical Immunology, 2002, 22, 23-27.	2.0	42
142	Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT Trial. Journal of the National Cancer Institute, 2020, 112, 1030-1037.	3.0	42
143	Integration of Human Papillomavirus Vaccination and Cervical Cancer Screening in Latin America and the Caribbean. Vaccine, 2008, 26, L88-L95.	1.7	40
144	Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methods. BMC Infectious Diseases, 2015, 15, 544.	1.3	40

#	Article	IF	CITATIONS
145	Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI. Oral Oncology, 2020, 108, 104736.	0.8	40
146	Correlates of IL-10 and IL-12 concentrations in cervical secretions. Journal of Clinical Immunology, 2003, 23, 175-183.	2.0	39
147	Familial Tendency and Risk of Nasopharyngeal Carcinoma in Taiwan: Effects of Covariates on Risk. American Journal of Epidemiology, 2011, 173, 292-299.	1.6	39
148	HPV16 Seropositivity and Subsequent HPV16 Infection Risk in a Naturally Infected Population: Comparison of Serological Assays. PLoS ONE, 2013, 8, e53067.	1.1	39
149	Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals. Molecular and Cellular Probes, 2012, 26, 73-80.	0.9	37
150	Evaluation of Human Leukocyte Antigen-A (HLA-A), Other Non-HLA Markers on Chromosome 6p21 and Risk of Nasopharyngeal Carcinoma. PLoS ONE, 2012, 7, e42767.	1.1	37
151	Human Leukocyte Antigens and Epstein–Barr Virus-Associated Nasopharyngeal Carcinoma: Old Associations Offer New Clues into the Role of Immunity in Infection-Associated Cancers. Frontiers in Oncology, 2013, 3, 299.	1.3	37
152	Single Nucleotide Polymorphisms in the PRDX3 and RPS19 and Risk of HPV Persistence and Cervical Precancer/Cancer. PLoS ONE, 2012, 7, e33619.	1.1	37
153	Distribution of Epstein-Barr viral load in serum of individuals from nasopharyngeal carcinoma high-risk families in Taiwan. International Journal of Cancer, 2006, 118, 780-784.	2.3	36
154	Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses. Human Vaccines and Immunotherapeutics, 2013, 9, 1399-1406.	1.4	35
155	Determinants of seropositivity among HPV-16/18 DNA positive young women. BMC Infectious Diseases, 2010, 10, 238.	1.3	34
156	Contribution of <i>TMC6</i> and <i>TMC8</i> (<i>EVER1</i> and <i>EVER2</i>) variants to cervical cancer susceptibility. International Journal of Cancer, 2012, 130, 349-355.	2.3	34
157	Comparison of Ophthalmic Sponges for Measurements of Immune Markers from Cervical Secretions. Vaccine Journal, 2004, 11, 399-405.	3.2	33
158	Increased plasma levels of adipokines and inflammatory markers in older women with persistent HPV infection. Cytokine, 2011, 53, 282-285.	1.4	33
159	Persistence of Concurrent Infections with Multiple Human Papillomavirus Types: A Population-based Cohort Study. Journal of Infectious Diseases, 2011, 203, 823-827.	1.9	33
160	High Levels of Antibody that Neutralize B-cell Infection of Epstein–Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma. Clinical Cancer Research, 2016, 22, 3451-3457.	3.2	33
161	Lowered Risk of Nasopharyngeal Carcinoma and Intake of Plant Vitamin, Fresh Fish, Green Tea and Coffee: A Case-Control Study in Taiwan. PLoS ONE, 2012, 7, e41779.	1.1	33
162	Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial. BMJ, The, 2015, 351, h4358.	3.0	32

#	Article	IF	CITATIONS
163	Whole-Exome Sequencing of Nasopharyngeal Carcinoma Families Reveals Novel Variants Potentially Involved in Nasopharyngeal Carcinoma. Scientific Reports, 2019, 9, 9916.	1.6	32
164	Prospects for a prophylactic HPV vaccine: Rationale and future implications for cervical cancer screening. Diagnostic Cytopathology, 1998, 18, 5-9.	0.5	31
165	A prospective study of immune and inflammation markers and risk of lung cancer among female never smokers in Shanghai. Carcinogenesis, 2017, 38, 1004-1010.	1.3	31
166	Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes. Journal of Hepatology, 2021, 74, 1132-1144.	1.8	30
167	Longâ€ŧerm risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment. International Journal of Cancer, 2012, 131, 211-218.	2.3	29
168	Low risk of typeâ€specific carcinogenic HPV reâ€appearance with subsequent cervical intraepithelial neoplasia grade 2/3. International Journal of Cancer, 2012, 131, 1874-1881.	2.3	29
169	Cytokine and Chemokine Profiles following Vaccination with Human Papillomavirus Type 16 L1 Virus-Like Particles. Vaccine Journal, 2007, 14, 984-989.	3.2	28
170	Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine. Vaccine, 2010, 28, 5407-5413.	1.7	28
171	Seroprevalence and Correlates of Human Papillomavirus 16/18 Seropositivity Among Young Women in Costa Rica. Sexually Transmitted Diseases, 2010, 37, 706-714.	0.8	27
172	Impact of Human Papillomavirus Vaccination on Cervical Cytology Screening, Colposcopy, and Treatment. American Journal of Epidemiology, 2013, 178, 752-760.	1.6	26
173	Circulating inflammatory markers and colorectal cancer risk: A prospective caseâ€cohort study in Japan. International Journal of Cancer, 2018, 143, 2767-2776.	2.3	26
174	Evaluation of a Novel PCR-Based Assay for Detection and Identification of <i>Chlamydia trachomatis</i> Serovars in Cervical Specimens. Journal of Clinical Microbiology, 2007, 45, 3986-3991.	1.8	25
175	Factors Associated with Fluctuations in IgA and IgG Levels at the Cervix during the Menstrual Cycle. Journal of Infectious Diseases, 2009, 199, 455-463.	1.9	25
176	Cancer patterns in nasopharyngeal carcinoma multiplex families in Taiwan. International Journal of Cancer, 2009, 124, 1622-1625.	2.3	25
177	Association of inflammatory and other immune markers with gallbladder cancer: Results from two independent case-control studies. Cytokine, 2016, 83, 217-225.	1.4	25
178	Prediagnostic circulating markers of inflammation and risk of oesophageal adenocarcinoma: a study within the National Cancer Institute Cohort Consortium. Gut, 2019, 68, 960-968.	6.1	25
179	Association of human leukocyte antigens with nasopharyngeal carcinoma in high-risk multiplex families in Taiwan. Human Immunology, 2009, 70, 910-914.	1.2	24
180	Direct Comparison of HPV16 Serological Assays Used to Define HPV-NaÃ⁻ve Women in HPV Vaccine Trials. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1547-1554.	1.1	24

#	Article	IF	CITATIONS
181	Performance of Self-Collected Cervical Samples in Screening for Future Precancer Using Human Papillomavirus DNA Testing. Journal of the National Cancer Institute, 2014, 107, dju400-dju400.	3.0	24
182	Comparison of Antibody Responses to Human Papillomavirus Vaccination as Measured by Three Assays. Frontiers in Oncology, 2014, 3, 328.	1.3	24
183	Common Genetic Variation in <i>TP53</i> and Risk of Human Papillomavirus Persistence and Progression to CIN3/Cancer Revisited. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1631-1637.	1.1	23
184	Human Leukocyte Antigen Class I and II Alleles and Cervical Adenocarcinoma. Frontiers in Oncology, 2014, 4, 119.	1.3	23
185	Association of circulating inflammation proteins and gallstone disease. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1920-1924.	1.4	23
186	The Association between the Comprehensive Epstein–Barr Virus Serologic Profile and Endemic Burkitt Lymphoma. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 57-62.	1.1	23
187	Gene Expression Patterns Induced by HPV-16 L1 Virus-Like Particles in Leukocytes from Vaccine Recipients. Journal of Immunology, 2009, 182, 1706-1729.	0.4	22
188	Invited Commentary: Circulating Inflammation Markers and Cancer RiskImplications for Epidemiologic Studies. American Journal of Epidemiology, 2013, 177, 14-19.	1.6	22
189	Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus. BMC Infectious Diseases, 2014, 14, 120.	1.3	22
190	HLAandKIRAssociations of Cervical Neoplasia. Journal of Infectious Diseases, 2018, 218, 2006-2015.	1.9	22
191	No association between genetic polymorphisms of CYP1A1, GSTM1, GSTT1, GSTP1, NAT2, and nasopharyngeal carcinoma in Taiwan. Cancer Epidemiology Biomarkers and Prevention, 2003, 12, 179-80.	1.1	22
192	Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. , 2011, 2011, .		21
193	Occupational exposure to diesel engine exhaust and alterations in immune/inflammatory markers: a cross-sectional molecular epidemiology study in China. Carcinogenesis, 2017, 38, 1104-1111.	1.3	21
194	CD83 polymorphisms and cervical cancer risk. Gynecologic Oncology, 2009, 114, 319-322.	0.6	20
195	molBV reveals immune landscape of bacterial vaginosis and predicts human papillomavirus infection natural history. Nature Communications, 2022, 13, 233.	5.8	20
196	An Examination of HPV16 Natural Immunity in Men Who Have Sex with Men (MSM) in the HPV in Men (HIM) Study. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 496-502.	1.1	19
197	Distribution of dysplasia and cancer in the gallbladder: an analysis from a high cancer-risk population. Human Pathology, 2018, 82, 87-94.	1.1	19
198	Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials. Journal of the National Cancer Institute, 2020, 112, 818-828.	3.0	19

#	Article	IF	CITATIONS
199	Etiology and Prevention of Cervical Adenocarcinomas. Journal of the National Cancer Institute, 2006, 98, 292-293.	3.0	18
200	Epidemiology of Genital Chlamydia trachomatis Infection Among Young Women in Costa Rica. Sexually Transmitted Diseases, 2008, 35, 461-468.	0.8	18
201	Evaluation of the Polyclonal ELISA HPV Serology Assay as a Biomarker for Human Papillomavirus Exposure. Sexually Transmitted Diseases, 2011, 38, 976-982.	0.8	18
202	Switch from cytologyâ€based to human papillomavirus testâ€based cervical screening: Implications for colposcopy. International Journal of Cancer, 2012, 130, 1879-1887.	2.3	18
203	Evaluation of a multiplex panel of immuneâ€related markers in cervical secretions: A methodologic study. International Journal of Cancer, 2014, 134, 411-425.	2.3	18
204	Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections. Journal of Infectious Diseases, 2016, 213, 939-947.	1.9	18
205	Premature Years of Life Lost Due to Cancer in the United States in 2017. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2591-2598.	1.1	18
206	Racial Differences in <i>Helicobacter pylori</i> CagA Sero-prevalence in a Consortium of Adult Cohorts in the United States. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2084-2092.	1.1	18
207	Evaluation of the FTA Carrier Device for Human Papillomavirus Testing in Developing Countries. Journal of Clinical Microbiology, 2012, 50, 3870-3876.	1.8	17
208	Reduced Prevalence of Vulvar HPV16/18 Infection Among Women Who Received the HPV16/18 Bivalent Vaccine: A Nested Analysis Within the Costa Rica Vaccine Trial. Journal of Infectious Diseases, 2014, 210, 1890-1899.	1.9	17
209	Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica. Vaccine, 2015, 33, 2141-2151.	1.7	17
210	Evaluation of TypeSeq, a Novel High-Throughput, Low-Cost, Next-Generation Sequencing-Based Assay for Detection of 51 Human Papillomavirus Genotypes. Journal of Infectious Diseases, 2019, 220, 1609-1619.	1.9	17
211	DNAse treatment following thawing of Cryopreserved PBMC is a procedure suitable for lymphocyte functional studies. Journal of Immunological Methods, 2006, 313, 209-213.	0.6	16
212	Evaluation of Two Types of Sponges Used To Collect Cervical Secretions and Assessment of Antibody Extraction Protocols for Recovery of Neutralizing Anti-Human Papillomavirus Type 16 Antibodies. Vaccine Journal, 2008, 15, 60-64.	3.2	16
213	Impact of freeze-thaw cycles on circulating inflammation marker measurements. Cytokine, 2017, 95, 113-117.	1.4	16
214	Risk of HPV-16/18 Infections and Associated Cervical Abnormalities in Women Seropositive for Naturally Acquired Antibodies: Pooled Analysis Based on Control Arms of Two Large Clinical Trials. Journal of Infectious Diseases, 2018, 218, 84-94.	1.9	16
215	Genetic Admixture and Population Substructure in Guanacaste Costa Rica. PLoS ONE, 2010, 5, e13336.	1.1	16
216	A comparison of single and combined visual, cytologic, and virologic tests as screening strategies in a region at high risk of cervical cancer. Cancer Epidemiology Biomarkers and Prevention, 2003, 12, 815-23.	1.1	16

#	Article	IF	CITATIONS
217	Neither oneâ€time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer. International Journal of Cancer, 2009, 125, 1649-1656.	2.3	15
218	Circulating Levels of Inflammatory Proteins and Survival in Patients with Gallbladder Cancer. Scientific Reports, 2018, 8, 5671.	1.6	15
219	Evaluation of nasal and nasopharyngeal swab collection for the detection of Epsteinâ€Barr virus in nasopharyngeal carcinoma. Journal of Medical Virology, 2018, 90, 191-195.	2.5	15
220	Evaluation of the antibody response to the EBV proteome in EBVâ€associated classical Hodgkin lymphoma. International Journal of Cancer, 2020, 147, 608-618.	2.3	15
221	Patterns of Human Leukocyte Antigen Class I and Class II Associations and Cancer. Cancer Research, 2021, 81, 1148-1152.	0.4	15
222	Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial. Vaccine, 2022, 40, 76-88.	1.7	15
223	Invited Commentary: Epstein-Barr Virus-Based Screening for the Early Detection of Nasopharyngeal CarcinomaA New Frontier. American Journal of Epidemiology, 2013, 177, 251-253.	1.6	14
224	Characterization of ELISA detection of broadâ€spectrum antiâ€Epstein–Barr virus antibodies associated with nasopharyngeal carcinoma. Journal of Medical Virology, 2013, 85, 524-529.	2.5	14
225	Effect of Different Human Papillomavirus Serological and DNA Criteria on Vaccine Efficacy Estimates. American Journal of Epidemiology, 2014, 180, 599-607.	1.6	14
226	Circulating immune/inflammation markers in Chinese workers occupationally exposed to formaldehyde. Carcinogenesis, 2015, 36, 852-857.	1.3	14
227	Association between Regular Aspirin Use and Circulating Markers of Inflammation: A Study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 825-832.	1.1	14
228	Circulating inflammatory proteins and gallbladder cancer: Potential for risk stratification to improve prioritization for cholecystectomy in high-risk regions. Cancer Epidemiology, 2018, 54, 25-30.	0.8	14
229	T cell receptor repertoire among women who cleared and failed to clear cervical human papillomavirus infection: An exploratory proof-of-principle study. PLoS ONE, 2018, 13, e0178167.	1.1	14
230	Circulating inflammation markers and colorectal adenoma risk. Carcinogenesis, 2019, 40, 765-770.	1.3	14
231	Cigarette smoking increases the risk of nasopharyngeal carcinoma through the elevated level of IgA antibody against Epsteinâ€Barr virus capsid antigen: A mediation analysis. Cancer Medicine, 2020, 9, 1867-1876.	1.3	14
232	Validation of an Epstein-Barr Virus Antibody Risk Stratification Signature for Nasopharyngeal Carcinoma by Use of Multiplex Serology. Journal of Clinical Microbiology, 2020, 58, .	1.8	14
233	Immunologic markers and risk of hepatocellular carcinoma in hepatitis B virus―and hepatitis C virusâ€infected individuals. Alimentary Pharmacology and Therapeutics, 2021, 54, 833-842.	1.9	14
234	Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium. Journal of Clinical Oncology, 2022, 40, 3613-3622.	0.8	14

#	Article	IF	CITATIONS
235	The von Hippel-Lindau (VHL) disease tumor-suppressor gene is not mutated in nasopharyngeal carcinomas. International Journal of Cancer, 1995, 61, 437-438.	2.3	13
236	Patterns of Interindividual Variability in the Antibody Repertoire Targeting Proteins Across the Epstein-Barr Virus Proteome. Journal of Infectious Diseases, 2018, 217, 1923-1931.	1.9	13
237	Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines. Vaccine, 2006, 24, S227-S232.	1.7	12
238	A Bayesian method for risk window estimation with application to HPV vaccine trial. Computational Statistics and Data Analysis, 2017, 112, 53-62.	0.7	12
239	Design and statistical considerations for studies evaluating the efficacy of a single dose of the human papillomavirus (HPV) vaccine. Contemporary Clinical Trials, 2018, 68, 35-44.	0.8	12
240	Lack of heterogeneity of HPV16 E7 sequence compared with HPV31 and HPV73 may be related to its unique carcinogenic properties. Archives of Virology, 2010, 155, 367-370.	0.9	11
241	Establishment and Operation of a Biorepository for Molecular Epidemiologic Studies in Costa Rica. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 916-922.	1.1	11
242	Application of multiplex arrays for cytokine and chemokine profiling of bile. Cytokine, 2015, 73, 84-90.	1.4	11
243	Evaluation of serological assays to monitor antibody responses to single-dose HPV vaccines. Vaccine, 2020, 38, 5997-6006.	1.7	11
244	Partial Least Square Discriminant Analysis Discovered a Dietary Pattern Inversely Associated with Nasopharyngeal Carcinoma Risk. PLoS ONE, 2016, 11, e0155892.	1.1	11
245	Determinants and Correlation of Systemic and Cervical Concentrations of Total IgA and IgG. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2672-2676.	1.1	10
246	Lipopolysaccharide-pathway proteins are associated with gallbladder cancer among adults in Shanghai, China with mediation by systemic inflammation. Annals of Epidemiology, 2016, 26, 704-709.	0.9	10
247	Cervical cancer incidence after screening with HPV, cytology, and visual methods: 18‥ear followâ€up of the Guanacaste cohort. International Journal of Cancer, 2017, 140, 1926-1934.	2.3	10
248	Trends in cervical cancer incidence in younger US women from 2000 to 2013. Gynecologic Oncology, 2017, 144, 391-395.	0.6	10
249	The Natural History of Oral Human Papillomavirus in Young Costa Rican Women. Sexually Transmitted Diseases, 2017, 44, 442-449.	0.8	10
250	A Prospective Study of Circulating Chemokines and Angiogenesis Markers and Risk of Multiple Myeloma and Its Precursor. JNCI Cancer Spectrum, 2020, 4, pkz104.	1.4	10
251	Simultaneous measurement of several cytokines using small volumes of biospecimens. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 1477-84.	1.1	10
252	HPV16 E6 seropositivity among cancer-free men with oral, anal or genital HPV16 infection. Papillomavirus Research (Amsterdam, Netherlands), 2016, 2, 141-144.	4.5	9

#	Article	IF	CITATIONS
253	Circulating inflammationâ€related markers and advanced gastric premalignant lesions. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 852-856.	1.4	9
254	Prospective assessment of a nasopharyngeal carcinoma risk score in a population undergoing screening. International Journal of Cancer, 2021, 148, 2398-2406.	2.3	9
255	Comparison of new magnetic resonance imaging grading system with conventional endoscopy for the early detection of nasopharyngeal carcinoma. Cancer, 2021, 127, 3403-3412.	2.0	9
256	Oral Immunoglobulin Levels are Not a Good Surrogate for Cervical Immunoglobulin Levels. Frontiers in Oncology, 2012, 2, 61.	1.3	8
257	Industrial hog farming is associated with altered circulating immunological markers. Occupational and Environmental Medicine, 2018, 75, 212-217.	1.3	8
258	Multilaboratory Assessment of Epstein-Barr Virus Serologic Assays: the Case for Standardization. Journal of Clinical Microbiology, 2019, 57, .	1.8	8
259	Reproducibility, Temporal Variability, and Concordance of Serum and Fecal Bile Acids and Short Chain Fatty Acids in a Population-Based Study. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1875-1883.	1.1	8
260	Alterations of T ell surface markers in older women with persistent human papillomavirus infection. International Journal of Cancer, 2011, 128, 597-607.	2.3	7
261	A prospective study of absolute risk and determinants of human papillomavirus incidence among young women in Costa Rica. BMC Infectious Diseases, 2013, 13, 308.	1.3	7
262	Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay. Human Vaccines and Immunotherapeutics, 2014, 10, 2965-2974.	1.4	7
263	Associations between self-reported diabetes and 78 circulating markers of inflammation, immunity, and metabolism among adults in the United States. PLoS ONE, 2017, 12, e0182359.	1.1	7
264	Evaluation of Total and IgA-Specific Antibody Targeting Epstein-Barr Virus Glycoprotein 350 and Nasopharyngeal Carcinoma Risk. Journal of Infectious Diseases, 2018, 218, 886-891.	1.9	7
265	Circulating sCD27 and sCD30 in preâ€diagnostic samples collected fifteen years apart and future nonâ€Hodgkin lymphoma risk. International Journal of Cancer, 2019, 144, 1780-1785.	2.3	7
266	Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma. MSphere, 2020, 5, .	1.3	7
267	Efficacy of ASO4-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study. Journal of Infectious Diseases, 2021, 223, 1576-1581.	1.9	7
268	HLA Zygosity Increases Risk of Hepatitis B Virus-Associated Hepatocellular Carcinoma. Journal of Infectious Diseases, 2021, , .	1.9	7
269	Utility of Epstein–Barr Virus DNA in Nasopharynx Swabs as a Reflex Test to Triage Seropositive Individuals in Nasopharyngeal Carcinoma Screening Programs. Clinical Chemistry, 2022, 68, 953-962.	1.5	7
270	Inflammatory profiles in Chilean Mapuche and non-Mapuche women with gallstones at risk of developing gallbladder cancer. Scientific Reports, 2021, 11, 3686.	1.6	6

#	Article	IF	CITATIONS
271	Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing. Cancer, 1997, 81, 89-97.	2.0	6
272	HPV vaccination in women aged 24–45 years. Lancet, The, 2009, 374, 1239.	6.3	5
273	Longitudinal Analysis of Carcinogenic Human Papillomavirus Infection and Associated Cytologic Abnormalities in the Guanacaste Natural History Study: Looking Ahead to Cotesting. Journal of Infectious Diseases, 2012, 205, 498-505.	1.9	5
274	Number of Human Papillomavirus Vaccine Doses and Condyloma. JAMA - Journal of the American Medical Association, 2014, 311, 2439.	3.8	5
275	Beasley's 1981 paper: The power of a well-designed cohort study to drive liver cancer research and prevention. Cancer Epidemiology, 2018, 53, 195-199.	0.8	5
276	Human Papillomavirus Vaccines. , 2018, , 430-455.e10.		5
277	Evaluation of Rare and Common Variants from Suspected Familial or Sporadic Nasopharyngeal Carcinoma (NPC) Susceptibility Genes in Sporadic NPC. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1682-1686.	1.1	5
278	Association Between Common Vaginal Infections and Cervical Non–Human Papillomavirus (HPV) 16/18 Infection in HPV-Vaccinated Women. Journal of Infectious Diseases, 2021, 223, 445-451.	1.9	5
279	Epstein-Barr Virus-Based Nasopharyngeal Carcinoma (NPC) Risk Prediction Scores Are Elevated in NPC Multiplex Family Members in Taiwan. Journal of Infectious Diseases, 2021, 223, 441-444.	1.9	5
280	Association between immunologic markers and cirrhosis in individuals with chronic hepatitis B. Scientific Reports, 2021, 11, 21194.	1.6	5
281	Using Immune Marker Panels to Evaluate the Role of Inflammation in Cancer: Summary of an NCI-Sponsored Workshop. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1427-1433.	1.1	4
282	Household coal combustion, indoor air pollutants, and circulating immunologic/inflammatory markers in rural China. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2019, 82, 411-421.	1.1	4
283	Prediagnostic serum sCD27 and sCD30 in serial samples and risks of nonâ€Hodgkin lymphoma subtypes. International Journal of Cancer, 2020, 146, 3312-3319.	2.3	4
284	Risk Factors for Non–Human Papillomavirus (HPV) Type 16/18 Cervical Infections and Associated Lesions Among HPV DNA–Negative Women Vaccinated Against HPV-16/18 in the Costa Rica Vaccine Trial. Journal of Infectious Diseases, 2021, 224, 503-516.	1.9	4
285	Human leukocyte antigen class I alleles and cervical neoplasia: no heterozygote advantage. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 419-20.	1.1	4
286	Characterization of the humoral immune response to the EBV proteome in extranodal NK/T-cell lymphoma. Scientific Reports, 2021, 11, 23664.	1.6	4
287	Reply to P.E. Castle. Journal of Clinical Oncology, 2014, 32, 361-362.	0.8	3
288	0282†A cross-sectional study of markers of early immunological and cardiovascular health effects among a population exposed to carbon nanotubes: the CANTES study0282†A cross-sectional study of markers of early immunological and cardiovascular health effects among a population exposed to carbon nanotubes: the CANTES study. Occupational and Environmental Medicine, 2014, 71, A35.2-A35.	1.3	3

#	Article	IF	CITATIONS
289	Association Between Human Leukocyte Antigen Class I and II Diversity and Non-virus-associated Solid Tumors. Frontiers in Genetics, 2021, 12, 675860.	1.1	3
290	Elevated antibodies against Epstein–Barr virus among individuals predicted to carry nasopharyngeal carcinoma susceptibility variants. Journal of General Virology, 2018, 99, 1268-1273.	1.3	3
291	Cancer patterns in nasopharyngeal carcinoma multiplex families over 15 years. Cancer, 2021, 127, 4171-4176.	2.0	2
292	Response to "Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of ASO4 adjuvanted vaccines―by Verstraeten et al Vaccine, 2009, 27, 2529.	1.7	1
293	Improved genetic association tests for an ordinal outcome representing the disease progression process. Genetic Epidemiology, 2011, 35, n/a-n/a.	0.6	1
294	Birth order and risk of nasopharyngeal carcinoma in multiplex families from <scp>T</scp> aiwan. International Journal of Cancer, 2016, 139, 2467-2473.	2.3	1
295	Soluble cluster of differentiation 14 levels elevated in bile from gallbladder cancer cases from Shanghai, China. Scientific Reports, 2021, 11, 13405.	1.6	1
296	HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial. Npj Vaccines, 2022, 7, 40.	2.9	1
297	Reply to P.A. LeppĂ k ioto. Journal of Clinical Oncology, 2009, 27, 3066-3067.	0.8	0
298	Longitudinal Study of Human Papillomavirus Persistence and Cervical Intraepithelial Neoplasia Grade 2/3: Critical Role of Duration of Infection. Obstetrical and Gynecological Survey, 2010, 65, 374-376.	0.2	0
299	0442â€Elucidating mechanisms using comparative molecular epidemiology: Immunologic alterations in workers exposed to trichloroethylene and formaldehyde. Occupational and Environmental Medicine, 2014, 71, A125-A125.	1.3	0
300	Fewer than three doses of HPV vaccine – Authors' reply. Lancet Oncology, The, 2015, 16, e424-e425.	5.1	0
301	O41-4â€Altered circulating immune and inflammation markers among hog farmers in the study of biomarkers of exposure and effect in agriculture. , 2016, , .		0
302	O18-5â€Occupational exposure to diesel exhaust and alterations in immune/inflammatory markers. , 2016, , .		0
303	O08-2â€Occupational exposure to benzene and alterations in immune/inflammatory markers. , 2016, , .		0
304	FIVE AUTHORS REPLY. American Journal of Epidemiology, 2018, 187, 399-399.	1.6	0
305	Abstract 4824: Little evidence of human papillomavirus in lung tumor tissue. , 2010, , .		0
306	Abstract 5073: Serum sCD23 and sCD30 associated with non-Hodgkin lymphoma risk as far as 15 to 23		0

years after blood collection. , 2014, , .

#	Article	IF	CITATIONS
307	Abstract 2920: Circulating inflammation markers and subsequent lung cancer risk: A discovery and replication study. , 2014, , .		0
308	Identifying Epstein-Barr virus peptide sequences associated with differential IgG antibody response. International Journal of Infectious Diseases, 2021, 114, 65-71.	1.5	0
309	Analysis of cervical HPV infections among unvaccinated young adult women to inform vaccine strategies in this age group: the Costa Rica HPV Vaccine Trial. Sexually Transmitted Infections, 0, , sextrans-2022-055434.	0.8	0